Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Collaboration to Provide Clinical Trial Services in the United Kingdom for Study Data Capture, Processing, and Reporting

By BiotechDaily International staff writers
Posted on 25 Feb 2013
Merge Healthcare, Inc. (Chicago, IL, USA), a provider of clinical systems, announced that NorthWise Services (NWS; Sittingbourne, UK) has collaborated with Merge and selected eClinical OS (operating system) to gather, manage, and report on clinical trials data across all studies.

NWS is a specialist contract research organization (CRO) providing services in data management, statistics, and medical writing. Its services are complementary to the offerings of Merge, which has allowed a strong and active working partnership to develop.

“NWS has always supported products at the forefront of eClinical technology, but in the past this tended to be separated into different software tools for EDC, ePRO, IVR, etc.,” explained Dr. Philip North, managing director of NorthWise Services. “It is therefore very appealing now to be able to access a wide range of eClinical functions on a single web-based platform, with just one user login and password.”

Recognizing the potential benefits of eClinical OS in collecting, managing, and reporting clinical trials data across all stages, NWS has arranged to have its own eClinical OS-certified study builder, who can now build studies for clients using eClinical OS.

“We were pleased with how easy it was for our study builder to become qualified and certified in the use of eClinical OS,” continued Dr. North. “Merge provided NWS access to eClinical OS in a sandbox environment during the self-training process. Because of this, the qualification was quickly and entirely achieved, using only the extensive online training materials available within eClinical OS. The built-in training materials were intuitive and thorough. Our staff did not require any additional help from Merge—though that would have been available if needed.”

Cost transparency using eClinical OS’s self-service quoting tool was also a benefit to NWS. “The cost calculator tool has been very valuable,” added Dr. North. “Not only is Merge eClinical OS competitive in the eClinical marketplace, but this tool allows us to remain competitive when bidding on a new study with our sponsor clients.”

“With eClinical OS, NWS has deep visibility into the cost of its studies,” said Justin Dearborn, president of Merge Healthcare. “We designed a cost calculator into the system which allows our clients to generate their own quotes and create budget scenarios in real-time. This provides them with the decision support tools to balance options and costs.”

Merge eClinical OS provides end-to-end study support through a single, easy-to-use interface allowing clients to manage and run studies more effectively. It provides built-in study templates, libraries, and reports to help users create studies quickly and manage them effectively without technical, assistance. Merge eClinical OS works for the largest and smallest studies, has the flexibility to support trials in any phase, and captures any type of data, from any source, from any modality.

Merge’s enterprise and cloud-based systems for image intensive specialties provide access to any image, 24/7. Merge also provides health stations, clinical trials software and other health data and analytics solutions that engage consumers in their personal health.

NorthWise Services provides a range of services, including data management, statistics, and medical writing, to the biotechnology, pharmaceutical, and other industries, and other products and services through strategic working alliances.

Related Links:
Merge Healthcare
NorthWise Services


comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Drug Discovery

view channel
Image: The new peptide offers a triple hormone effect in a single-cell molecule (Photo courtesy of Indiana University).

Tripeptide Drug Effectively Controls Metabolic Syndrome in Rodent Model

Promising results in reducing obesity and normalizing glucose metabolism obtained with a synthetic dipeptide drug have been enhanced by the addition of a molecule of a third hormone, glucagon.... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.